Meta-Analysis of Shenqi Fuzheng Injection as an Adjuvant Therapy for the Treatment of Cervical Cancer

Abstract

Background: The present study aimed to systemically evaluate the safety and clinical efficacy of Shenqi Fuzheng injection (SFI) combined with conventional treatment for cervical cancer. Methods: Studies investigating the effect of SFI plus conventional treatment versus conventional treatment until 19 April 2021, were systematically reviewed. RevMan 5.3 software (The Nordic Cochrane Centre, Copenhagen, Denmark) was utilized for the present data analysis. Results: Eight articles were included in this study. Patients in the SFI group had better complete remission (CR) [risk ratio (RR) 95% confidence interval (95% CI) = 1.69 (1.02, 2.82), p = 0.04], partial remission (PR) [RR (95% CI) = 1.78 (1.21, 2.64), p = 0.004], objective response rate (ORR) [RR (95% CI) = 1.76 (1.36, 2.30), p < 0.0001], improved quality of life (RR (95% CI) = 1.80 (1.30, 2.49), p = 0.0004), improved plus stable quality of life (RR (95% CI) = 1.27 (1.10, 1.46), p = 0.001), more CD3+ T cell [weighted mean difference (WMD) (95% CI) = 9.76 (5.79, 13.73), p < 0.00001], CD4+ T cell (WMD (95% CI) = 8.16 (6.36, 9.95), p < 0.00001), NK (natural killer) cell (WMD (95% CI) = 3.16 (0.02, 6.31), p = 0.05), higher CD4/CD8 (WMD (95% CI) = 0.64 (0.23, 1.05), p = 0.002), less CD8+ T cell (WMD (95% CI) = –5.66 (–8.18, –3.13), p < 0.0001), and less risk of leukopenia (RR (95% CI) = 0.52 (0.38, 0.69), p < 0.00001) and nausea or vomiting (RR (95% CI) = 0.59 (0.45, 0.77), p = 0.0001). Conclusions: SFI combined with conventional treatment exhibited better therapeutic efficacy and safety than those of conventional chemotherapy.